While the data presented in this report provides compelling benefits of rescuing hPRL signaling in mice for PDX modeling of ER+ breast cancer, it is likely that correction of additional key molecular incompatibilities between mice and humans will be needed to further harmonize biology and drug responsiveness of patient tumors and PDX tumor lines. The gene discussed is PRLR; the disease is breast cancer.